Allergic Rhinitis Clinical Trial
Official title:
Efficacy and Safety of Birch Pollen Immunotherapy in Local Allergic Rhinitis
Local allergic rhinitis (LAR) is relatively new disease. The question of effect of allergen specific immunotherapy on LAR is open. The randomized, double blind placebo controlled trial of birch subcutaneous AIT on LAR were performed in twenty eight patients. The therapy was performed during 24 months in proportion 15 patients with AIT and 13 placebo. The primary endpoint was decreased of symptoms medication score (SMS). Additionally monitoring serum specific IgE, specific IgG4 and nasal specific IgE (nsIgE) to Bet v1 and parameters of safety and quality of life were provided.
Local allergic rhinitis (LAR) is still an under diagnosed and under treated disease. It is
characterised by local production of IgE during natural exposure to aeroallergens. These
patients have negative skin prick tests and serum-specific IgEs but have positive nasal
provocation tests for aeroallergens. More than 50% of patients with chronic non-allergic
rhinitis may have a problem with lack of LAR diagnosis. Misdiagnosis can lead to mistakes in
the treatment as well as inefficiencies.
Besides on only local IgE-mediated reaction, allergen immunotherapy (AIT) could be a
potential way of treatment such patients. However, there are only sufficient data that the
AIT is effective in allergic rhinoconjunctivitis and asthma to pollens and house dust mites
and some animal.
The aim of this study was to assess the safety and efficacy of AIT for birch pollen
allergens in patients with local allergic rhinitis and a confirmed birch pollen allergy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05080322 -
Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis
|
Phase 4 | |
| Recruiting |
NCT06028490 -
A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis.
|
Phase 2 | |
| Completed |
NCT04388358 -
Traditional Chinese Medicine for the Treatment of Perennial Allergic Rhinitis on Gut Microbiota and Immune-modulation
|
N/A | |
| Recruiting |
NCT04202263 -
Assessment of Suppression of Cutaneous Allergic Responses and Pruritis by Topical Minocycline
|
Phase 2 | |
| Completed |
NCT04078009 -
Standardising Nasal Allergen Challenge in Adult With Hay Fever
|
N/A | |
| Completed |
NCT03644680 -
Changes in Adaptive Immune Responses and Effector Cell Responses Upon Nasal Allergen Exposure - a Pilot Study
|
N/A | |
| Completed |
NCT04541004 -
Adolescent Mite Allergy Safety Evaluation
|
Phase 3 | |
| Recruiting |
NCT05378594 -
HDM and Silver Birch NAC Standardisation
|
N/A | |
| Not yet recruiting |
NCT05684380 -
Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)
|
Phase 3 | |
| Not yet recruiting |
NCT01014325 -
Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy
|
Phase 3 | |
| Completed |
NCT02943720 -
ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen
|
Phase 2 | |
| Completed |
NCT02910401 -
Clinical Response to Rhinovirus Challenge
|
Phase 2 | |
| Completed |
NCT02556801 -
Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy
|
Phase 2 | |
| Completed |
NCT02352168 -
Airway Inflammation in Children With Allergic Rhinitis and Intervention
|
N/A | |
| Not yet recruiting |
NCT02233426 -
Effect of Hypertonic Solutions on Allergic Rhinitis Patients
|
N/A | |
| Completed |
NCT01918956 -
PURETHAL Birch RUSH Study
|
Phase 4 | |
| Completed |
NCT01946035 -
Alpha-Blockers in Allergic Rhinitis (MAN 01)
|
Phase 4 | |
| Completed |
NCT01682070 -
SUBLIVAC FIX Phleum Pratense DT/DRF
|
Phase 2 | |
| Recruiting |
NCT01454492 -
The Relationship Between Allergic Rhinitis and Geographic Tongue
|
N/A | |
| Completed |
NCT01439815 -
An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo
|
Phase 4 |